The submission of early results (1 year) TRAM flap data gathered by the Division of Plastic Reconstructive & Aesthetic Surgery at NUH Singapore is titled: Early results with rectus sheath repair using a TIGR® Matrix Surgical Mesh (TIGR® Matrix) following pedicled TRAM flap surgery for breast reconstruction; and documents early results with the use of a synthetic resorbable mesh – TIGR® Matrix as an on-lay graft over a rectus sheath repair in patients who had undergone pedicled TRAM flap for breast reconstruction.
The pedicled transverse rectus abdominis myocutaneous (TRAM) flap is a workhorse of autologous breast reconstruction. The main drawback most surgeons have with this option is in the donor site morbidity. Very often, the rectus sheath cannot be closed primarily and the defect has to be bridged using a mesh. Even if the rectus sheath can be apposed, the patient is at risk of having an abdominal hernia from weakness of the abdominal wall. The ideal situation would be to use a non-permanent on-lay graft over the primary repair to strengthen the sheath repair. The graft would give additional strength until fibrosis has set in to provide the additional strength to the repair, and yet the mesh would then resorb, to minimize the problems associated with the use of a permanent mesh.
40 patients in total were recuited. 20 for the study group where TIGR ® Matrix was implanted, the other 20 served as controls. All patients were randomized into either using this synthetic resorbable mesh or a synthetic permanent mesh. Data was collected prospectively, as well as on follow up up to 1 year.
The results showed that there was no significant difference in complication rates between the two groups, up to a follow up of 1 year. There was no difference in patient recovery, hospitalization stay, and pain scores.
TIGR® Matrix Surgical Mesh may be a suitable resorbable on-lay mesh for use in repair of the rectus sheath after TRAM flap surgery.
Wei Chen ONG (1,2), Jane LIM (2), Eileen Chor Hoong HING (1,2), N. Vigneswaran (2), Hanjing LEE (2), Yan Lin YAP (2), Marcus WONG (3), Thiam Chye LIM (1,2)
1 Yong Loo Lin School of Medicine, National University of Singapore
2 Division of Plastic, Reconstructive and Aesthetic Surgery, Department of Surgery, National University Health System (NUHS)
3 Plastic, Reconstructive & Aesthetic Surgery, Tan Tock Seng Hospital, Singapore
About Novus Scientific
Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable (100% absorbable) synthetic medical devices. Global HQ is in Singapore while European Headquarters and the core R&D function are in Uppsala, Sweden. The company’s roots are Swedish as all the founders of Novus Scientific are previous owners / senior managers / members of the soft tissue-engineering project within Uppsala-based, Radi Medical Systems AB (now owned by St. Jude Medical Inc). The US Division, Novus Scientific, Inc. is headquartered in San Diego. From this hub, Novus Scientific, Inc. distributes TIGR® Matrix Surgical Mesh (TIGR® Matrix) throughout the United States.
TIGR® Matrix - The world’s 1st long-term resorbable, 100% absorbable synthetic mesh with unique patented dual-fiber construction, designed for gradually increasing mechanical compliance and mtr is available in two sizes; 10x15cm (NSTM1015) and 20x30cm (NSTM2030) and has had FDA (510k) clearance since February 2010 and CE mark approval since August 2011.
TIGR® Matrix Surgical Mesh is intended for use in reinforcement of soft tissue where weakness exists, in procedures involving the repair of hernias and abdominal wall defects, abdominal wall reinforcement and muscle flap reinforcement according to CE approval and in the United States is indicated for use for reinforcement of soft tissue where weakness exists.
TIGR® is a registered trademark of Novus Scientific Pte. Ltd